First-generation precision cancer medicine approaches have largely involved molecular profiling of a patient’s tumour (often by DNA sequencing), and seeking to identify driver genetic alterations for which targeted therapies are available. Whilst this can yield real clinical benefit for a minority of patients, Dr. Baird will consider some of the major challenges to this approach, and how these might be overcome by innovative approaches including seamless clinical trials and adaptive / treatment-switching strategies.